Page 33 - IMR Annual Report 2022: Institute for Medical Research

Annual
IMR
Report2022 17
INSTITUTE FOR MEDICAL RESEARCH

CaRC Research Highlights

Principal
investigator/
No. Research Title NMRR Co-principal
Number
investigator
(Co-PI)

1 Digital PCR as a potential platform for quantitative NMRR-19- Co-PI: Aliza
analysis of BCR-ABL1 in evaluating response to 1899-49315 Mohd Yacob
treatment in chronic myeloid leukaemia: A systematic
review

2 The study of regulatory function of miRNAs in acute NMRR-19- Dr. Ezalia Esa
myeloid leukaemia 2148-48481

3 Genetic variation associated with bortezomib induced NMRR-19- Dr. Sujatha
peripheral neuropathy in adult multiple myeloma 2274-48525 Suthandiram
patients

4 Long non-coding RNAs (lncRNAs) profilling in beta NMRR-19- Dr. Norafiza
thalassaemia patients 2280-48428 Mohd Yasin

5 Identification of new primate adenovirus subtypes for NMRR-19- Co-PI:
development into replication-deficient adeno-vectors 2705-50872 Dr. Tan Lu
backbones Ping

6 Transcriptomic profiling for genetic characterization of NMRR-20- Nor Soleha
multiple myeloma patients with drug resistance: A pilot 2408-56967 Mohd Dali
study

7 Molecular profiling and risk treatment stratification NMRR-20- Dr. Ermi
of acute promyelocytic leukaemia by whole exome 3009-57145 Neiza Mohd
sequencing Sahid

8 Pre-clinical evaluation of human mesenchymal stem NMRR-20- Dr. Lim Moon
cells (hMSCs) derived exosome eye drops 3011-57629 Nian
9 Epigenetic alterations in Malaysian primary acute NMMR-20- Nor Rizan
myeloid leukemia patients: Prognosis and treatment 3013-57079 Kamaluddin

10 Circulating tumour cells for the prognosis of breast NMRR-21- Co-PI: Dr Tan
cancer 359-58705 Lu Ping

11 Sequencing of circulating tumour DNA in Malaysian NMRR-21- Dr. Yuslina
patients with diffuse large b cell lymphoma using liquid 452-58907 Mat Yusoff
biopsy approach

12 Dynamic tracking of Cytopeutics® Human Umbilical NMRR-21- Low Chui
Cord Mesenchymal Stem Cells (huc-MSC) by 643-59215 Thean
intravenous administration route in healthy mice and (ISR)
following lipopolysaccharide-induced organ injury and
systemic inflammation Centre (CaRC) Cancer Research

13 Pre-clinical in vitro efficacy of modified mesenchymal RSCH ID- Dr. Shaik
stem cells expressing decoy ACE2 and IL-37 for 21-01696- Ahmad
elimination of SARS-CoV-2 and attenuation of acute LD9 Kamal Shaik
respiratory distress syndrome M Fakiruddin